Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity.
| Autor: | Freed-Pastor WA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: william_freed-pastor@dfci.harvard.edu., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: andrew_aguirre@dfci.harvard.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer cell [Cancer Cell] 2022 Sep 12; Vol. 40 (9), pp. 908-910. |
| DOI: | 10.1016/j.ccell.2022.08.018 |
| Abstrakt: | Covalent inhibitors of oncogenic KRAS G12C have demonstrated impressive clinical responses; however, therapeutic resistance has been commonly observed. In this issue, Zhang and colleagues demonstrate that small molecule KRAS G12C inhibitors can generate haptenated major histocompatibility complex (MHC) class I:peptide complexes, which represent attractive targets for immune-based therapies to combat pharmacologic resistance. Competing Interests: Declaration of interests A.J.A. has consulted for Arrakis Therapeutics, Syros Pharmaceuticals, Boehringer Ingelheim, T-knife Therapeutics, AstraZeneca, Mirati Therapeutics, Revolution Medicines, Anji Pharmaceuticals, and Merck & Co., Inc. A.J.A. consults for and holds equity in Riva Therapeutics. A.J.A. has research funding from Mirati Therapeutics, Syros Pharmaceuticals, Bristol Myers Squibb, Revolution Medicines, Novartis, Novo Ventures and Deerfield, Inc. W.A.F-P. has consulted for PMV Pharma and holds equity in Regeneron. W.A.F-P. receives research support from Arcus Biosciences and Apexigen. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|